Cencora, Inc. (NYSE:COR) Shares Bought by Iowa State Bank

Iowa State Bank lifted its position in shares of Cencora, Inc. (NYSE:COR) by 3.2% in the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 6,375 shares of the company’s stock after acquiring an additional 198 shares during the period. Iowa State Bank’s holdings in Cencora were worth $1,432,000 as of its most recent filing with the SEC.

Several other hedge funds have also recently bought and sold shares of COR. Arizona State Retirement System increased its stake in shares of Cencora by 6.3% in the second quarter. Arizona State Retirement System now owns 52,047 shares of the company’s stock valued at $11,726,000 after purchasing an additional 3,089 shares during the period. Private Advisor Group LLC grew its holdings in Cencora by 11.5% in the 2nd quarter. Private Advisor Group LLC now owns 6,785 shares of the company’s stock worth $1,529,000 after buying an additional 700 shares in the last quarter. Candriam S.C.A. raised its stake in Cencora by 21.9% during the 2nd quarter. Candriam S.C.A. now owns 7,897 shares of the company’s stock valued at $1,779,000 after acquiring an additional 1,420 shares in the last quarter. Savant Capital LLC raised its stake in Cencora by 2.1% during the 2nd quarter. Savant Capital LLC now owns 6,511 shares of the company’s stock valued at $1,467,000 after acquiring an additional 132 shares in the last quarter. Finally, SRS Capital Advisors Inc. boosted its position in Cencora by 6.7% during the 2nd quarter. SRS Capital Advisors Inc. now owns 3,338 shares of the company’s stock worth $752,000 after acquiring an additional 210 shares during the period. 97.52% of the stock is currently owned by institutional investors.

Cencora Trading Up 0.1 %

Shares of NYSE:COR traded up $0.15 during midday trading on Monday, reaching $229.35. The company had a trading volume of 361,763 shares, compared to its average volume of 930,216. The company has a fifty day simple moving average of $237.44 and a two-hundred day simple moving average of $233.60. The company has a debt-to-equity ratio of 4.84, a quick ratio of 0.53 and a current ratio of 0.88. The firm has a market cap of $44.33 billion, a price-to-earnings ratio of 30.54, a price-to-earnings-growth ratio of 1.54 and a beta of 0.45. Cencora, Inc. has a 1-year low of $208.58 and a 1-year high of $253.27.

Cencora Increases Dividend

The company also recently disclosed a quarterly dividend, which was paid on Friday, November 29th. Shareholders of record on Friday, November 15th were given a dividend of $0.55 per share. This represents a $2.20 annualized dividend and a yield of 0.96%. This is a boost from Cencora’s previous quarterly dividend of $0.51. The ex-dividend date was Friday, November 15th. Cencora’s payout ratio is presently 29.29%.

Analysts Set New Price Targets

A number of equities research analysts recently weighed in on COR shares. Bank of America restated a “neutral” rating and set a $245.00 price objective (down from $275.00) on shares of Cencora in a research note on Wednesday, September 18th. Barclays boosted their price target on shares of Cencora from $263.00 to $290.00 and gave the stock an “overweight” rating in a research report on Thursday, November 7th. StockNews.com cut shares of Cencora from a “strong-buy” rating to a “buy” rating in a report on Friday, September 20th. Wells Fargo & Company dropped their target price on Cencora from $249.00 to $237.00 and set an “equal weight” rating on the stock in a report on Friday, December 13th. Finally, Mizuho began coverage on Cencora in a research note on Wednesday, December 4th. They set an “outperform” rating and a $280.00 price target for the company. Two investment analysts have rated the stock with a hold rating and ten have given a buy rating to the company. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $275.60.

Insider Activity

In related news, Chairman Steven H. Collis sold 21,509 shares of Cencora stock in a transaction on Tuesday, November 19th. The stock was sold at an average price of $242.16, for a total transaction of $5,208,619.44. Following the completion of the sale, the chairman now owns 306,752 shares of the company’s stock, valued at approximately $74,283,064.32. This trade represents a 6.55 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Silvana Battaglia sold 1,678 shares of the stock in a transaction on Friday, December 20th. The stock was sold at an average price of $228.72, for a total transaction of $383,792.16. Following the transaction, the executive vice president now owns 20,329 shares in the company, valued at approximately $4,649,648.88. This trade represents a 7.62 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 94,696 shares of company stock worth $22,862,734 over the last quarter. Corporate insiders own 15.80% of the company’s stock.

Cencora Company Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.